New Hope for Severe Liver Failure Patients: Promising Drug Nangibotide Enters Next Phase of Testing

The company GENFIT has shared new research supporting the potential of a drug called nangibotide to treat a serious liver condition called acute-on-chronic liver failure, or ACLF. This condition occurs when liver problems suddenly worsen, causing severe inflammation and damage to multiple organs in the body. A new clinical study to test nangibotide’s safety and effectiveness in ACLF patients is expected to begin before the end of 2026, with initial results anticipated by the second half of 2027. The findings were presented at a major liver health conference in Denver, where experts in liver disease discussed the latest advances in treatment options.nnNangibotide is designed to calm down an overactive immune response that contributes to ACLF. It works by targeting a specific pathway in the body called TREM-1, which acts like a signal booster for inflammation. By reducing this excessive inflammation, nangibotide aims to prevent the condition from worsening without weakening the body’s ability to fight infections.nnPrevious research has shown that an overactive TREM-1 pathway may speed up the progression from mild liver problems to ACLF, and is linked to more severe disease and worse outcomes. GENFIT has already tested nangibotide in other serious inflammatory conditions, including septic shock and COVID-19, involving a total of 416 patients. In these studies, the drug was found to be as safe as a placebo, and no major safety concerns were identified.nnIn a group of 118 patients with septic shock who had high levels of TREM-1, those treated with nangibotide showed a greater improvement in organ function compared to those given a placebo. They also had better trends in survival rates and other health outcomes. In another study of 219 COVID-19 patients, nangibotide was linked to better overall health and a lower risk of death within 28 days.nnDr. Jennifer C. Lai, a liver specialist and professor at the University of California, San Francisco, highlighted the urgent need for better treatments for ACLF, especially for patients in intensive care who can quickly develop life-threatening multi-organ failure. She noted that nangibotide is not starting from scratch, as it has already been studied in other serious inflammatory conditions with promising results. This gives researchers a unique opportunity to see if the drug’s benefits can extend to ACLF patients, who currently have very few effective treatment options. She stated, ‘What is especially exciting about nangibotide is that we are not starting from scratch: the program already benefits from substantial phase 2 clinical experience and proof-of-concept in acute inflammatory conditions characterized by organ dysfunction.’ She added, ‘This gives us a rare opportunity to bring an already extensively studied clinical-stage candidate into ACLF and explore whether those signals can translate into meaningful benefit for these critically ill patients.’

Leave a Comment

Scroll to Top